Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Burchert

Showing results (51-60 of 109) with videos related to

Pageof 11
Sort By:
Leukemia & Lymphoma|January 16, 2019
Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogenic stem cell transplantationDeborah Christen, Kristina Sohlbach, Stephan K Metzelder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous LeukemiaSieghart Sopper, Satu Mustjoki, Deborah White, et al.
Clinical and Translational Medicine|April 3, 2024
Reciprocal crosstalk between Th17 and mesothelial cells promotes metastasis-associated adhesion of ovarian cancer cellsFelix Neuhaus, Sonja Lieber, Veronika Shinkevich, et al.
NPJ Digital Medicine|March 21, 2024
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligenceJan-Niklas Eckardt, Waldemar Hahn, Christoph Röllig, et al.
Haematologica|December 4, 2019
Cloning and characterization of a novel druggable fusion kinase in acute myeloid leukemiaChristian Michel, Elisabeth K.M. Mack, Christopher-Nils Mais, et al.
Leukemia|November 3, 2023
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuationJani Huuhtanen, Shady Adnan-Awad, Jason Theodoropoulos, et al.
Journal of Clinical Medicine|September 23, 2018
The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic CancerDetlef K Bartsch, Norman Gercke, Konstantin Strauch, et al.
The Lancet. Haematology|March 19, 2018
Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trialFrederick Fasslrinner, Johannes Schetelig, Andreas Burchert, et al.
Haematologica|March 5, 2026
Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenibRadwan Massoud, Sarah Flossdorf, Franziska Hanke, et al.
Bone Marrow Transplantation|April 8, 2026
Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignanciesAndrea Gantner, Svenja Labuhn, Daniel Fürst, et al.
Pageof 11

Showing results (51-60 of 109) with videos related to

Sort By:
Pageof 11
Leukemia & Lymphoma|January 16, 2019
Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogenic stem cell transplantationDeborah Christen, Kristina Sohlbach, Stephan K Metzelder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous LeukemiaSieghart Sopper, Satu Mustjoki, Deborah White, et al.
Clinical and Translational Medicine|April 3, 2024
Reciprocal crosstalk between Th17 and mesothelial cells promotes metastasis-associated adhesion of ovarian cancer cellsFelix Neuhaus, Sonja Lieber, Veronika Shinkevich, et al.
NPJ Digital Medicine|March 21, 2024
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligenceJan-Niklas Eckardt, Waldemar Hahn, Christoph Röllig, et al.
Haematologica|December 4, 2019
Cloning and characterization of a novel druggable fusion kinase in acute myeloid leukemiaChristian Michel, Elisabeth K.M. Mack, Christopher-Nils Mais, et al.
Leukemia|November 3, 2023
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuationJani Huuhtanen, Shady Adnan-Awad, Jason Theodoropoulos, et al.
Journal of Clinical Medicine|September 23, 2018
The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic CancerDetlef K Bartsch, Norman Gercke, Konstantin Strauch, et al.
The Lancet. Haematology|March 19, 2018
Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trialFrederick Fasslrinner, Johannes Schetelig, Andreas Burchert, et al.
Haematologica|March 5, 2026
Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenibRadwan Massoud, Sarah Flossdorf, Franziska Hanke, et al.
Bone Marrow Transplantation|April 8, 2026
Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignanciesAndrea Gantner, Svenja Labuhn, Daniel Fürst, et al.
Pageof 11